Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use

Authors

  • Francisco J. Navarro-Triviño Department of Contact Eczema and Immunoallergic Diseases, Hospital Universitario San Cecilio, Granada, Spain
  • Mario Lozano-Lozano Department of Physical Therapy, Faculty of Health Sciences, and University of Granada & Sport and Health Joint University Institute (iMUDS), Granada, Spain
  • Ricardo Ruiz-Villaverde Department of Psoriasis, Dermatology, Hospital Universitario San Cecilio, Granada, Spain https://orcid.org/0000-0002-0381-6174

Keywords:

adherence, satisfaction, calcipotriol/bethamethasone, aersolo foam, psoriasis

Abstract

Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD).  

Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life.

Methods: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales.

Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied.

Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence.

References

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM.; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377‐385. DOI: 10.1038/jid.2012.339. PMID: 23014338.

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983‐994. DOI: 10.1016/S0140-6736(14)61909-7.

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205‐212. DOI: 10.1111/jdv.13854.PMID: 27573025.

Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol. 2010;24(9):989‐1004. DOI: 10.1111/j.1.468-3083.2010.03705.x. PMID: 20477920.

Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii83‐ii86. DOI: 10.1136/ard.2004.030791. PMID: 15708945.

Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33(6):1107‐1115. DOI: 10.1111/jdv.15369. PMID: 30472749.

Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;CD005028. DOI: 10.1002/14651858.CD005028.pub3. PMID: 23543539.

Basse LH, Olesen M, Lacour JP, Queille-Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:s33 (abst 192).

Queille-Roussel C, Olesen M, Villumsen J, Lacour JP. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35(4):239‐245. DOI: 10.1007/s40261-015-0269-7. PMID: 25708531.

Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2016;20(1):44‐51. DOI: 10.1177/1203475415597094. PMID: 26224733.

Leonardi C, Bagel J, Yamauchi P, et al. The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health-related quality of life in patients with psoriasis vulgaris: results from the randomized PSO-FAST study. J Drugs Dermatol. 2016;15(8):981‐987. PMID: 27537999.

Stein Gold L, Lebwohl M, Menter A, Villumsen J, Rosen M, Koo J. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15(8):951‐957. PMID: 27537995.

Pink AE, Jalili A, Berg P, et al. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol. 2019;33(6):1116‐1123. DOI: 10.1111/jdv.15398. PMID: 30916417.

Reich K, Daudén E. Treatment adherence: a hurdle for real-life effectiveness in psoriasis? J Eur Acad Dermatol Venereol. 2014;28 Suppl 2:1‐3. DOI: 10.1111/jdv.12442. PMID: 24684737.

Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119‐126. DOI: 10.1111/jdv.13859. PMID: 27531752.

Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607‐613. DOI: 10.1016/j.jaad.2005.12.021. PMID: 17010739.

Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25 Suppl 4:9‐14. DOI: 10.1111/j.1468-3083.2011.04060.x. PMID: 21507078.

Balak DMW, Carrascosa JM, Gregoriou S, et al. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. J Dermatolog Treat. 2020 Mar 6;1‐8. DOI: 10.1080/09546634.2019.1707754. PMID: 31940225.

Duvetorp A, Levin LÅ, Engerstedt Mattsson E, Ryttig L. A cost-utility analysis of calcipotriol/betamethasone dipropionate aerosol foam versus ointment for the topical treatment of psoriasis vulgaris in Sweden. Acta Derm Venereol. 2019;99(4):393‐399. DOI: 10.2340/00015555-3112. PMID: 30628631.

Gerdes S, Velasco M, Wu JJ, Hubo M, Veverka KA. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). J Dermatolog Treat. 2020;Jan 28;1‐11. DOI: 10.1080/09546634.2020.1717417. PMID: 31986945.

Amat-Samaranch V, Puig L. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):423‐432. DOI: 10.1080/14740338.2020.1749594. PMID: 32243212.

Røpke M, Bulai Livideanu C, Kaldate R, Snel A, Paul C. Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study. Br J Dermatol. 2018;178(1):e33‐e34. DOI: 10.1111/bjd.15814. PMID: 28722136.

Queille-Roussel C, Nielsen J, Lacour JP. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. J Dermatolog Treat. 2019;30(6):529‐533. DOI: 10.1080/09546634.2018.1529385. PMID: 30582717.

Downloads

Published

2021-05-20

Issue

Section

Research

How to Cite

1.
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use. Dermatol Pract Concept [Internet]. 2021 May 20 [cited 2024 Mar. 29];:2021056. Available from: https://dpcj.org/index.php/dpc/article/view/dermatol-pract-concept-articleid-dp1103a56